A股異動丨智飛生物大升13% GSK向公司獨家供應重組帶狀皰疹疫苗
智飛生物(300122.SZ)大幅高開,現大升逾13%,最高報55.55元創逾5個月新高價,總市值1304億元。10月8日,公司與葛蘭素史克生物、葛蘭素史克香港(以下合稱:"GSK")簽署了《獨家經銷和聯合推廣協議》,GSK將向智飛生物獨家供應重組帶狀皰疹疫苗,並許可智飛生物根據約定在合作區域內(係指中國大陸)營銷、推廣、進口並經銷有關產品。此外,協議還約定GSK將優先在合作區域內任何RSV老年人疫苗的聯合開發和商業化方面成為智飛生物的獨家合作伙伴。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.